Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

ticker cardiology pty ltd - 60724 - medical image management system application software - the ticker toolbox software is a picture archiving and communications system (pacs) and cardiology report display system used with a general purpose computer, a computer server, specific client computers and mobile devices. it provides communication, storage and reformatting on the client computer of dicom compliant medical images. it provides storage and display on the server component, converted dicom compliant medical images to web compliant video and images and storage and display of cardiology reports. it can supply information for the purpose of detecting and diagnosing physiological conditions. this software does not drive or influence another medical device.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - 41670 - radiology picture archiving and communication system application software - resolutionmd software is an enterprise medical image viewer used with off-the-shelf servers, web browsers, and specific mobile devices for the 2d display, multi-planar reformatting and 3d visualization of medical image data and reports. it provides collaboration and integrated secure audiovideo communication, and displays dicom and non-dicom medical images and reports. resolutionmd is intended for use as a diagnostic, review, and analysis tool by trained healthcare professionals to drive clinical management. when interpreted by a trained physician, reviewed images may be used to aid in diagnosis. when used on a mobile device, resolutionmd is not intended to replace full radiology workstations. resolutionmd is not to be used for primary mammography diagnoses.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); mannitol; sodium lauryl sulfate; ethylcellulose; polysorbate 80; magnesium stearate; hyprolose; purified talc; iron oxide yellow; povidone; light magnesium oxide; propylene glycol; titanium dioxide - rabeprazole is indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - Inggeris - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - chlorothalonil - water dispersible granule - chlorothalonil benzene active 900.0 g/kg - fungicide

Australia - Inggeris - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sabakem pty ltd - chlorothalonil - suspension concentrate - chlorothalonil benzene active 720.0 g/l - fungicide

Australia - Inggeris - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - chlorothalonil - water dispersible granule - chlorothalonil benzene active 900.0 g/kg - fungicide

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

intermed medical pty ltd - sodium tetradecyl sulfate, quantity: 10 mg/ml - injection, solution - excipient ingredients: benzyl alcohol; dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections; sodium hydroxide - the solution is designed for injection directly into the lumen of the varicose vein and is used as a sclerosant in the treatment of uncomplicated varicose veins of the leg by compression sclerotherapy. the strength of fibrovein selected depends on the size of the veins to be treated. fibrovein 3% is for the treatment of large superficial varicose veins. fibrovein 1% is for the treatment of small varicose veins and the larger venules. minor venules and spider veins (venous flares) should be treated with fibrovein 0.5% or 0.2%. the selection of the incorrect strength particularly in the case of minor venules and spider veins is liable to give risk to adverse reactions.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

intermed medical pty ltd - sodium tetradecyl sulfate, quantity: 2 mg/ml - injection, solution - excipient ingredients: benzyl alcohol; dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections; sodium hydroxide - the solution is designed for injection directly into the lumen of the varicose vein and is used as a sclerosant in the treatment of uncomplicated varicose veins of the leg by compression sclerotherapy. the strength of fibrovein selected depends on the size of the veins to be treated. fibrovein 3% is for the treatment of large superficial varicose veins. fibrovein 1% is for the treatment of small varicose veins and the larger venules. minor venules and spider veins (venous flares) should be treated with fibrovein 0.5% or 0.2%. the selection of the incorrect strength particularly in the case of minor venules and spider veins is liable to give risk to adverse reactions.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

australasian medical & scientific ltd - sodium tetradecyl sulfate, quantity: 30 mg/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; sodium hydroxide - indications as at 09 june 2005 : the solution is designed for injection directly into the lumen of the varicose vein and is used as a sclerosant in the treatment of uncomplicated varicose veins of the leg by compression sclerotherapy. the strength of fibrovein selected depends on the size of the veins to be treated. fibrovein 3% is for the treatment of large superficial varicose veins. fibrovein 1% is for the treatment of small varicose veins and the larger venules. minor venules and spider veins (venous flares) should be treated with fibrovein 0.5% or 0.2%. the selection of the incorrect strength particularly in the case of minor venules and spider veins is liable to give rise to adverse reactions.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - 40867 - x-ray system, diagnostic, computed tomography, application program software - this device is intended to be used to prepare geometric and anatomical data relating to a proposed external beam radiotherapy treatment prior to dosimetry planning. anatomical volumes can be defined automatically or manually in three dimensions using a set of ct images acquired with the patient in the proposed treatment position. definition of the anatomical volumes may be assisted by additional ct, mr or pet studies that have been co-registered with the planning ct scan. additionally, ct & pet data from a respiratory tracked examination may be used to allow the user define the target or treatment volume over a defined range of the respiratory cycle. the geometric parameters of a proposed treatment field are selected to allow non-dosimetric,interactive optimization of field coverage. defined anatomical structures and geometric treatments fields are displayed on transverse images, on reformatted sagittal, coronal or oblique images, on 3 d views created from the images, or on a beam eye's view display with or without the display of defined structures with or without the display of digitally reconstructed radiograph.